Phathom Pharmaceuticals, Inc. Overview
Pro stress-test →Phathom Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. The company markets VOQUEZNA® (vonoprazan) for treating heartburn associated with Non-Erosive GERD, erosive GERD, and H. pylori infection, with triple and dual combination packs available for infection treatment.
Strategic Profile
Pro stress-test →Phathom's lead asset is vonoprazan, an oral small-molecule potassium competitive acid blocker that shows rapid, potent anti-secretory effects and has demonstrated clinical benefits in treating gastroesophageal reflux disease and H. pylori infection. The company's product aims to elevate stomach pH more effectively than PPI therapies, positioning itself for adoption among physicians serving an estimated 65 million patient market.
Competitive Landscape
Pro stress-test →Phathom competes in the GI therapeutics market against established PPI manufacturers and emerging PCAB developers. Crinetics Pharmaceuticals is noted as one of 34 identified competitors. Phathom's differentiation lies in vonoprazan's first-in-class PCAB mechanism and its superior acid elevation profile compared to traditional PPIs, establishing positioning as an innovative alternative in a large, well-defined market.
Industry Context
Phathom Pharmaceuticals, Inc. operates in Biopharmaceuticals - Gastrointestinal Therapeutics.
Key facts
Founded: 2018 · Headquarters: Florham Park, New Jersey, US · Revenue: $175M (TTM as of Dec 2025) · Market cap: $990M